CD274 and neoplasm: Finally, we compare the anti-tumor immune response in the HIS-CRC-BRGS mice to a fifth CRC PDX following treatment with Ca/N to another cohort treated with cobimetinib and atezolizumab (Co/A), a distinct combination therapy targeting tyrosine kinases and the PD-L1 pathway that has failed in the clinic in an effort to determine if these combinations result in differences in immune responses in vivo that may potentially explain the failure of Co/A in clinical trials and if Ca/N may be a superior immunotherapy combination in this patient population.